BofA Lifts Johnson & Johnson Price Target on Robust Pipeline Momentum

Bank of America’s decision to raise its price target for Johnson & Johnson (JNJ) marks a significant validation of the healthcare giant’s strategic pivot following the spin-off of its consumer health division, Kenvue. By shedding its lower-margin consumer brands, JNJ has effectively transformed into a pure-play innovation engine, focusing its capital and research efforts on the high-growth sectors of Innovative Medicine and MedTech. This analyst upgrade suggests that the market is beginning to fully price in the long-term value of JNJ’s refreshed portfolio, which is designed to offset upcoming patent expirations for legacy blockbusters.

At the heart of the BofA upgrade is the accelerating momentum within JNJ’s Innovative Medicine segment, formerly known as Janssen. Analysts are particularly bullish on the company’s oncology franchise, where therapies like Darzalex and the CAR-T cell therapy Carvykti continue to gain market share and expand into earlier lines of treatment. Furthermore, JNJ’s immunology pipeline, led by Tremfya, is showing resilience as the company prepares for the eventual biosimilar competition for Stelara. The ability to transition patients to newer, more effective therapies is a critical component of JNJ’s strategy to maintain its leadership in the immunology space through the end of the decade.

“

The integration of Abiomed, acquired for $16.6 billion, has significantly bolstered JNJ’s presence in the high-growth heart recovery market.

Beyond pharmaceuticals, JNJ’s MedTech division is emerging as a primary driver of the company’s valuation. The integration of Abiomed, acquired for $16.6 billion, has significantly bolstered JNJ’s presence in the high-growth heart recovery market. Investors are also closely watching the development of Ottava, JNJ’s next-generation robotic surgical system. As the MedTech landscape shifts toward digital and robotic-assisted surgery, JNJ’s ability to compete with incumbents like Intuitive Surgical will be a decisive factor in its long-term growth trajectory. BofA’s revised target reflects an expectation that these technological investments will begin to contribute more meaningfully to the bottom line in the 2026-2027 fiscal years.